ArticleNutrition & diabetes2017
Liraglutide reduces body weight by upregulation of adenylate cyclase 3.
Article in Nutrition & diabetes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Effects of liraglutide on gut bacterial community dynamics.Microbiology spectrum · 2026Article
- Threonic acid, an ascorbic acid metabolite, synergizes with intermittent fasting to ameliorate obesity.Experimental & molecular medicine · 2026Article
- A Rare Case of Monogenic Obesity Due to a Novel Variant in theJournal of clinical research in pediatric endocrinology · 2025Article
- A Combined GLP-1/PPARa/CB1-Based Therapy to Restore the Central and Peripheral Metabolic Dysregulation Induced by a High-Fructose High-Fat Diet.International journal of molecular sciences · 2025Article
- Article
- Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence.F1000Research · 2025Review
- Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway.Reproductive biology and endocrinology : RB&E · 2024Article
- Hypothalamic GABAergic Neurons Expressing Cellular Retinoic Acid Binding Protein 1 (CRABP1) Are Sensitive to Metabolic Status and Liraglutide in Male Mice.Neuroendocrinology · 2024Article
- Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics.British journal of pharmacology · 2022Review
- IGFBP6 Is Downregulated in Unstable Carotid Atherosclerotic Plaques According to an Integrated Bioinformatics Analysis and Experimental Verification.Journal of atherosclerosis and thrombosis · 2020Article
- Efficacy and safety of liraglutide in Indian adolescents with obesity.Obesity science & practice · 2019Article
- α-Cedrene protects rodents from high-fat diet-induced adiposity via adenylyl cyclase 3.International journal of obesity (2005) · 2019Article
- Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.Scientific reports · 2018Article
- Olfactory receptor 10J5 responding to α-cedrene regulates hepatic steatosis via the cAMP-PKA pathway.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAccording to recent studies, adenylate cyclase 3 (AC3) is associated with obesity. Liraglutide reduces blood glucose levels and body weight (BW). We performed a 2 × 2 factorial experiment to study the relationships among AC3, liraglutide and obesity and to obtain a more comprehensive understanding of the mechanisms underlying the physiological effects of liraglutide on obesity.
methodsA high-fat diet was used to induce obesity in C57BL/6J mice. Both the normal and obese mice were treated with liraglutide (1 mg kg
resultsThe administration of liraglutide significantly decreased the BW in obese mice and normal control mice. The BW of obese mice exhibited a more obvious decrease. Hepatic AC3 mRNA and protein levels and serum AC3 levels were significantly reduced in obese mice compared with those in normal control mice. The administration of liraglutide significantly increased the hepatic expression of the AC3 and GLP-1R mRNAs and proteins and serum AC3 levels. The hepatic expression of the AC3 mRNA and protein and serum AC3 levels were negatively correlated with BW loss in the liraglutide-treated group. Pearson's correlation coefficients for these comparisons are r=-0.448, P=0.048; r=-0.478, P=0.046; and r=-0.909, P=0.000, respectively.
conclusionsBased on our research, liraglutide reduces BW, possibly by increasing the expression of AC3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.